Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.56), $0.24 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $14.54 million.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.